204.92
-0.72 (-0.35%)
| Penutupan Terdahulu | 205.64 |
| Buka | 205.90 |
| Jumlah Dagangan | 275,927 |
| Purata Dagangan (3B) | 231,008 |
| Modal Pasaran | 4,086,338,304 |
| Harga / Pendapatan (P/E TTM) | 33.43 |
| Harga / Pendapatan (P/E Ke hadapan) | 24.10 |
| Harga / Jualan (P/S) | 15.51 |
| Harga / Buku (P/B) | 4.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -73.07% |
| Margin Operasi (TTM) | -80.87% |
| EPS Cair (TTM) | -7.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 46.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.56% |
| Nisbah Semasa (MRQ) | 5.27 |
| Aliran Tunai Operasi (OCF TTM) | 52.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 63.35 M |
| Pulangan Atas Aset (ROA TTM) | -1.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ligand Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.30 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.35% |
| % Dimiliki oleh Institusi | 100.00% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Chicago Capital, Llc | 31 Dec 2025 | 561,423 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 277.00 (Oppenheimer, 35.18%) | Beli |
| Median | 244.00 (19.07%) | |
| Rendah | 239.00 (HC Wainwright & Co., 16.63%) | Beli |
| Purata | 253.33 (23.62%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 202.85 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 11 Mar 2026 | 244.00 (19.07%) | Beli | 221.24 |
| Oppenheimer | 27 Feb 2026 | 277.00 (35.17%) | Beli | 198.31 |
| HC Wainwright & Co. | 24 Feb 2026 | 239.00 (16.63%) | Beli | 189.00 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KOZARICH JOHN W | - | 199.62 | -467 | -93,223 |
| REARDON ANDREW | - | 199.62 | -5,000 | -998,100 |
| Jumlah Keseluruhan Kuantiti Bersih | -5,467 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,091,323 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 199.62 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| REARDON ANDREW | Pegawai | 01 Apr 2026 | Jual automatik (-) | 5,000 | 199.62 | 998,100 |
| REARDON ANDREW | Pegawai | 01 Apr 2026 | Pelaksanaan pilihan | 5,000 | - | - |
| KOZARICH JOHN W | Pengarah | 01 Apr 2026 | Jual automatik (-) | 467 | 199.62 | 93,223 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |